Dr David Allsup


Senior Lecturer in Haematology, Honorary Consultant Hull University Teaching Hospitals NHS Trust

Role at Hull York Medical School

David Allsup is a Senior Lecturer in Haematology with an Honorary NHS appointment with Hull University Teaching Hospitals NHS Trust, based in the Queens Centre for Oncology and Haematology at Castle Hill Hospital. He is the local haemophilia director and has additional clinical interests in inherited and acquired platelet disorders. He is also the local lead for chronic lymphocytic leukaemia (CLL), in which he has a longstanding research interest.

Dr Allsup is a member of the BRIDGE-BPD consortium investigating the aetiology of rare disorders of haemostasis and also an active member of the NCRI CLL clinical trials subgroup as well as being a co-investigator on the phase III clinical trial FLAIR.

His research interests include platelet disorders, the biology of chronic lymphocytic leukaemia and novel therapeutic approaches for haematological malignancies.


Dr Allsup graduated from the University of Leicester with a degree in medicine in 1992 before undertaking general medical and haematological training in Sheffield and Liverpool. In 2000 he was appointed as a clinical lecturer in hematology during which time he investigated B-cell receptor signalling in chronic lymphocytic leukaemia.

He was appointed as a consultant haematologist in Hull University Teaching Hospitals NHS Trust in 2004 with specialist interests in chronic lymphocytic leukaemia and haemostasis. He continued with his research interests in chronic lymphocytic leukaemia and haemostasis and was appointed as Clinical Senior Lecturer in Haematology in the Hull York Medical School in 2018.

ResearchGate profile

Google Scholar profile


David's research interests are based on furthering the understanding of the pathophysiology of chronic lymphocytic leukaemia (CLL). Locally he has supervised several PhD projects based on the use of proteomics to identify prognostic subsets of CLL. He has a long-standing collaboration with Professor J Allan, University of Newcastle who has been investigating the genetic basis of chronic lymphocytic leukaemia. Additionally David collaborates with Dr Slupskys team at the University of Liverpool who have an interest in the role of Lck in CLL biology.

He is also the local lead for platelet disorders and haemostasis and collaborates on mutlicentre studies investigated the cellular and genetic basis of inherited platelet disorders.

Dr Allsup also has interests in novel therapeutic approaches and is chief investigator on the clinical aspect of a study investigating the role of a novel methodology termed bioimprinting developed in the Chemistry Department, University of Hull by Professor Paunov and his group.

As well as an interest in fundamental biology Dr Allsup also support clinical research in Hull being the local principle investigator on a variety of clinical trials including FLAIR, COSMIC, Myeloma XI, MUK8, GAPP, BRIDGE-BPD and ITP registry. 


David is enthusiastic about education and is actively involved in a variety of undergraduate teaching programmes. He has contributed to:-

Hull York Medical School phase I and II teaching programmes.

Hull York Medical School SSIP modules both in haematology and Haemostasis.

Postgraduate medical teaching for core medical trainees and specialist trainees in haematology.

Development of elearning materials for the administration of intrathecal chemotherapy and venous thromboembolism.

Supervision of postgraduate research degrees including MSc and PhD students.


Farmery JHR, Smith ML; NIHR BioResource - Rare Diseases, Lynch AG. Telomerecat: A ploidy agnostic method for estimating telomere length from whole genome sequencing data. Scientific Reports. 2018 Jan 22;8(1):1300. doi: 10.1038/s41598-017-14403-y. (Member of NIHR rare diseases consortium).

Till KJ, Allen JC, Talab F, Lin K, Allsup D, Cawkwell L, Bentley A, Ringshausen I, Duckworth AD, Pettitt AR, Kalakonda N, Slupsky JR. Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. Scientific Reports. 2017 Dec 1;7(1):16784. doi: 10.1038/s41598-017-17021-w.

Hadinnapola C, Bleda M, Haimel M, Screaton N, Swift A, Dorfmüller P, Preston SD, Southwood M, Hernandez-Sanchez J, Martin J, Treacy C, Yates K, Bogaard H, Church C, Coghlan G, Condliffe R, Corris PA, Gibbs S, Girerd B, Holden S, Humbert M, Kiely DG, Lawrie A, Machado R, MacKenzie Ross R, Moledina S, Montani D, Newnham M, Peacock A, Pepke-Zaba J, Rayner-Matthews P, Shamardina O, Soubrier F, Southgate L, Suntharalingam J, Toshner M, Trembath R, Noordegraaf AV, Wilkins MR, Wort SJ, Wharton J; NIHR BioResource–Rare Diseases Consortium; UK National Cohort Study of Idiopathic and Heritable PAH, Gräf S, Morrell NW. Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation. 2017 Nov 21;136(21):2022-2033. doi:10.1161/CIRCULATIONAHA.117.028351. Epub 2017 Sep 28. (Member of NIHR rare diseases consortium).

Collett L, Howard DR, Munir T, McParland L, Oughton JB, Rawstron AC, Hockaday A, Dimbleby C, Phillips D, McMahon K, Hulme C, Allsup D, Bloor A, Hillmen P. Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials. 2017 Aug 22;18(1):387. doi: 10.1186/s13063-017-2138-6.

Medlock J, Das A, Madden L, Allsup D, Paunov V. Cancer bioimprinting and cell shape recognition for diagnosis and targeted treatment. Chem Soc Rev. 2017 Aug 14;46(16):5110-5127. doi: 10.1039/c7cs00179g.

Pratt G, Yap C, Oldreive C, Slade D, Bishop R, Griffiths M, Dyer M, Fegan C, Oscier D, Pettitt A, Matutes E, Devereux S, Allsup D, Bloor A, Hillmen P, Follows G, Rule S, Moss P, Stankovic T. A phase I trial of the PARP inhibitor olaparib in patients with relapsed or refractory Chronic Lymphocytic Leukaemia, T-Prolymphocytic Leukaemia or Mantle Cell Lymphoma. Br J Haematol. 2017 Jun 23. doi: 10.1111/bjh.14793.

Results of the randomised phase IIB ARCTIC (Attenuated dose Rituximab with ChemoTherapy In CLL) trial of low dose Rituximab in previously untreated CLL. Howard D, Munir T, McParland L, Rawstron A, Milligan D, Schuh A, Hockaday A, Allsup D, Marshall S, Duncombe A, O’Dwyer J, Smith A, Longo R, Varghese A, Hillmen P. Leukaemia 2017. May 2. doi: 10.1038/leu.2017.96.

Law P, Sud A, Mitchell J, Henrion M, Broderick P, Vijayakrishnan J, Speedy H, Johnson D, Kaiser M, Weinhold N, Cooke R, Sunter N, Jackson G, Summerfield G, Harris R, Pettitt A, Allsup D, Carmichael J, Bailey J, Pratt G, Rahman T, Pepper C, Fegan C,Strandmann  E, Engert A, Försti A, Chen B, Hoffmann P, Noethen M, Eisele L, Jöckel K, Allan J,Swerdlow A, Goldschmidt H, Catovsky D, Morgan G, Hemminki K, Houlston R. (2016). Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. Scientific Reports 2017 Jan 23;7:41071. doi: 10.1038/srep41071 

Law P, Bernd S, Speedy H, Camp N, Sava G, Skibola C, Holroyd A, Vijai J, Sunter N, Nieters A, Bea S, Monnereau A, Martin-Garcia D, Goldin L, Clot G, Teras L, Quintela I, Birmann B, Jayne S, Cozen W, Smedby K, Lan Q, Dearden C, Brooks-Wilson A, Hall A, Purdue M, Mainou-Fowler T, Vajdic C, Jackson G, Cocco P, Zhang Y, Zheng T, Giles G, Lawrence C, Call T, Liebow M, Melbye M, Glimelius B, Glenn M, Curtin K, Diver W, Link B, Conde L, Bracci P, Holly E, Jackson R, Tinker L, Benavente Y, Boffetta P, Brennan P, Maynadie M, McKay J, Albanes D, Weinstein S, Wang Z, Caporaso N, Morton L, Severson R, Riboli E, Vineis P, Vermeulen R, Southey M, Milne R, Clavel J, Topka S, Spinelli J, Kraft P, Ennas M, Summerfield G, Ferri G, Harris R, Miligi L, Pettitt A, North K, Allsup D, Fraumeni J, Bailey J, Offit K, Pratt G, Hjalgrim H, Pepper C, Chanock S, Fegan C, Rosenquist R, Sanjose S, Carracedo A, Dyer M, Catovsky D, Campo E, Cerhan J, Allan J, Rothman N, Houlston R, Slager S. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukemia. Nature Communications 2017 Feb 6;8:14175. doi: 10.1038/ncomms14175

Arno G, Carss KJ, Hull S, Zihni C, Robson AG, Fiorentino A; UK Inherited Retinal Disease Consortium, Hardcastle AJ, Holder GE, Cheetham ME, Plagnol V; NIHR Bioresource - Rare Diseases Consortium, Moore AT, Raymond FL, Matter K, Balda MS, Webster AR. Biallelic Mutation of ARHGEF18, Involved in the Determination of Epithelial Apicobasal Polarity, Causes Adult-Onset Retinal Degeneration. Am J Hum Genet. 2017 Feb 2;100(2):334-342. doi: 10.1016/j.ajhg.2016.12.014. Epub 2017 Jan 26. (Member of NIHR rare diseases consortium).

Carss KJ, Arno G, Erwood M, Stephens J, Sanchis-Juan A, Hull S, Megy K, Grozeva D, Dewhurst E, Malka S, Plagnol V, Penkett C, Stirrups K, Rizzo R, Wright G, Josifova D, Bitner-Glindzicz M, Scott RH, Clement E, Allen L, Armstrong R, Brady AF, Carmichael J, Chitre M, Henderson RH, Hurst J, MacLaren RE, Murphy E, Paterson J, Rosser E, Thompson DA, Wakeling E, Ouwehand WH, Michaelides M, Moore AT; NIHR-BioResource Rare Diseases Consortium., Webster AR, Raymond FL. Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. American Journal Human Genetics. 2017 Jan 5;100(1):75-90. doi: 10.1016/j.ajhg.2016.12.003. (Member of NIHR rare diseases consortium).

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC Trial): a phase II randomised controlled trial protocol. Howard D, Munir T, Hockaday A, Rawstron A, Collett L, Oughton J, Allsup D, Bloor A, Phillips D, Hillmen P. Trials. 2016 Sep 20;17(1):456.

Johnson B, Lowe G, Futterer J, Lordkipanidzé M, MacDonald D,  Simpson M, Sánchez Guiú I, Drake S, Bem D, Leo V, Fletcher S, Dawood B, Rivera J, Allsup D, Biss T, Bolton-Maggs P, Collins P, Curry N, Grimley C, James B, Makris M, Motwani J, Pavord S,Talks K, Thachil J, Wilde J, Williams M, Harrison P, Gissen P, Mundell S, Mumford A, Daly M, Watson S, Morgan N. Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects. Haematologica. 2016 Oct;101(10):1170-1179.

Sava G, Speedy H, Di Bernardo M, Dyer M, Holroyd A, Sunter N, Mansouri L, Deaglio S, Karabon L, Frydecka I, Woszczyk D, Juliusson G, Smedby K, Jayne S, Majid A, Wang Y, Dearden C, Hall A, Mainou-Fowler T, Jackson G, Summerfield G, Harris R, Pettitt A, Allsup D, Bailey J, Pratt G, Pepper C, Fegan C, Rosenquist R, Catovsky D, Allan J, Houlston R. Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk. Leukemia. 2015 Mar;29(3):748-51.

Speedy HE, Di Bernardo MC, Sava GP, Dyer MJ, Holroyd A, Wang Y, Sunter NJ, Mansouri L, Juliusson G, Smedby KE, Roos G, Jayne S, Majid A, Dearden C, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Catovsky D, Allan JM, Houlston RS. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nature Genetics. 2014 Jan;46(1):56-60.

Lin T, Norris K, Heppel N, Pratt G, Allan J, Allsup D, Bailey J, Cawkwell L, Hills R, Grimstead J, Jones R, Britt-Compton B, Fegan C, Baird D,Pepper C. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. British Journal of Haematology. 2014 167(2):214-23.

Kashuba E, Eagle G, Bailey J, Evans P, Welham K, Allsup D, Cawkwell L. Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen. Journal of Proteomics. 2013 91:478-485.

Mazumdar R, Evans P, R Culpin, Bailey J, Allsup D. The automated monocyte count is independently predictive of overall and treatment-free survival in chronic lymphocytic leukaemia and of survival following first-line chemotherapy. Leukaemia Research. 2013 37(6):614-8.

Madden LA, Hayman YA, Underwood C, Vince RV, Greenman J, Allsup D, Ali S. Increased inducible heat shock protein 72 expression is associated with PBMC isolated from patients with haematological tumours. The Scandinavian Journal of Clinical and Laboratory Investigation. 2013 72(5):380-6.

Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, Johnson G,  Schuh A, Matutes E, Dearden C, Catovsky D, Radford J, Bloor A, Follows G, Devereux S, Kruger A, Blundell J, Agrawal S, Allsup D, Proctor S, Heartin E, Oscier D,  Hamblin T, Rawstron A and Hillmen P. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukaemia and deletion of TP53: Final results of the National Cancer Research Institute CLL206 Trial. Journal of Clinical Oncology. 2011 30(14):1647-55

Whittle A, Allsup DJ, Bailey JR. Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism. Leukaemia Research. 2010 35(3):419-21. (IF 2.2).

Pointon J, Eagle G, Bailey J, Evans P, Allsup D, Greenman J. Thalidomide enhances cyclophosphamide and dexamethasone-mediated cytotoxicity towards cultured chronic lymphocytic leukaemia cells. Oncology Reports. 2010 24:1315-1321.

Pratt G, Fenton J, Allsup D, Fegan C, Morgan G, Jackson G, Sunter N, Hall A, Irving J, Allan J. A polymorphism in the 3’ UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma. British Journal of Haematology. 2010 150(3):371-373.

Allan J, Sunter N, Bailey J, Pettitt A, Harris R, Pepper C, Fegan C, Hall A, Deignan L, Bacon C, Pointon J, Houlston R, Broderick P, Mainou-Fowler T, Jackson G, Summerfield G, Evans P, Strefford J, Parker A, Oscier D, Pratt G, Allsup D (2010). Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia. Leukaemia. 24(4):877-881.

Crowther-Swanepoel D, Broderick P, Di Bernardo M, Dobbins S, Torres M, Mansouri M, Ruiz-Ponte C, Enjanes A, Rosenquist R, Carracedo A, Jurlander J, Campo E, Juliusson G, Montserrat E, Smedby K, Dyer M, Matutes E, Deardon C, Sunter N, Hall A, Mainou-Fowler T, Jackson G, Summerfield G, Harris R, Pettitt A, Allsup D, Bailey J, Pratt G, Pepper C, Fegan C, Parker A, Oscier D, Allan J, Catovsky D, Houlston R. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukaemia risk. Nature Genetics. 2010 42:132-6.

Allsup D, Harris R, Baker P, Cawley J. Protein-tyrosine phosphatase activity maintains the viability of hairy cells and modulates their response to interferon-alpha. Leukaemia Lymphoma. 2008 49:2351-8.

Bernardo M, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, Sullivan K, Vijayakrishnan J, Wang Y, Pittman A, Sunter N, Hall A, Dyer M, Matutes E, Deardon C, Mainou-Fowler T, Jackson G, Summerfield G, Harris R, Pettitt A, Hillmen P, Allsup D, Bailey J, Pratt G, Pepper C, Fegan C, Allan J, Catovsky D, Houlston R. A genome-wide association study identifies chronic lymphocytic leukaemia susceptibility loci at 2q13, 2q37.1 (SP140), 6p25.3 (IRF4/MUM1), 11q24.1, 15q23, and 19q13.32 (PRKD2). Nature Genetics. 2008 40:1204-10.

Steedman B, Watson J, Ali S, Shields ML, Patmore R, Allsup D. Inhaled Nitrous Oxide (Entonox) as a short acting sedative during bone marrow examination. Clinical and Laboratory Haematology. 2006 28(5):321-324.

Kamiguti AS, Slupsky J, Harris RJ, Allsup D, Cawley JC, Zuzel M. PKC, Src Rac and ROS are central to the constitutive activation of hairy cells. Journal of Immunology. 2005 175:8424-8430. 

Allsup DJ, Lin K, Sherrington P, Matrai Z, Slupsky J, Cawley J, Zuzel M. B-cell receptor translocation into lipid rafts and associated signalling differs between prognostically important subgroups of chronic lymphocytic leukaemia. Cancer Research. 2005 65(16):7328-37.

Allsup D, Chu P. The use of amphotericin B lipid complex in 15 patients with presumed or proven fungal infection. British Journal of Haematology. 1998 102:1109-10.

Allsup DJ, Boarder MR. Comparison of P2 purinergic receptors of aortic endothelial cells with those of adrenal medulla: evidence for heterogeneity of receptor subtype and of inositol phosphate response. Molecular Pharmacology, 1990 38:84-91.


Review Articles

Soe ZN, Allsup D. The use of ofatumumab in the treatment of B-cell malignancies. Future Oncology. 2017 Aug 29. doi: 10.2217/fon-2017-0275.

Kashuba E, Bailey J, Allsup D, Cawkwell L. The Kinin-Kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers. Biomarkers. 2013 18(4):279-96.

Allsup DJ, Cawley JC. Diagnosis, biology and treatment of hairy cell leukaemia. Clinical and Experimental Medicine. 2004 4:132-138

Allsup DJ, Cawley JC. (2003) The diagnosis and treatment of hairy cell leukaemia. Blood Reviews, 16: 255-262. 


Book Chapter

Allsup, D., Ali, S., & Robinson, S. (n.d.). Hematological Malignancies in Pregnancy. In D. James, P. Steer, C. Weiner, B. Gonik, & S. Robson (Eds.), High-Risk Pregnancy: Management Options: Management Options(pp. 1006-1043). Cambridge: Cambridge University Press.

Allsup D and Small M (2009) Haematology in the elderly. In:- Practical Management of Older People in Primary Care (ed. Gosney M and Harris T) Oxford University Press, Oxford, UK. (pg 123-133). 

Pettitt AR, Sherrington P, Allsup DJ, Matrai Z, Cawley JC, Zuzel M (2004). Natural history of CLL: Current thinking. In: - UK Key Advances in Clinical Practice Series. Key Advances in the Effective Management of Chronic Lymphocytic Leukaemia. (ed. by T Hamblin, S Johnson & A Miles). Aesculapius Medical Press, London. (pg 39-61).

Case Reports

Dukka V, Allsup D. Perioperative Management of Type 2N Von Willebrand’s Disease with Recombinant Factor VIII in a Patient Undergoing Knee-Replacement Surgery. Case Reports in Hematology. 2013, Article ID 837906, 2 pages, 2013. doi:10.1155/2013/837906. 

Parrish C, Ming A, Patmore R, Shields M, Allsup D. Brachial plexopathy following high-dose melphalan and autologous peripheral blood stem cell transplantation. Bone marrow transplantation. 2010 45(5):951-952. 

Razzak A, Shields M, Allsup D. Autoimmune paraneoplastic cerebellar degeneration secondary to a composite lymphoma. Leukaemia and Lymphoma. 2007 48(7):1456-8. 

Corless JA, Allsup DJ, Deeble TJ, Delaney JC. A pulmonary mass and hyperviscosity. Postgraduate Medical Journal. 2000 76: 582, 587. 

Allsup D, Galvani D, Martlew V. Maternal and neonatal autoimmune thrombocytopenia. British Journal of Haematology. 1999 105:317.

Allsup D, Galvani D. A case of neonatal alloimmune thrombocytopenia complicated by preceding maternal idiopathic thrombocytopenic purpura. British Journal of Haematology. 1998 101:211.


David is actively collaborating with the organisations listed below. He is always interested in any collaborative project that can advance patient care or the understanding of haematological diseases.

University of Newcastle, Professor J Allan. Constitutional genetics and chronic lymphocytic leukaemia.

University of Liverpool, Dr J Slupsky. Role of Lck in chronic lymphocytic leukaemia.

University of Hull, Chemistry, Professor V Paunov. Development of bioimprinting technology for the treatment of leukaemias.

Genotyping and platelet phenotyping project (GAPP), University of Birmingham.

BRIDGE-BPD consortium, University of Cambridge.

Clinical trials unit, University of Leeds, member of the trial management group for the FLAIR randomised clinical trial, chief investigator Professor P Hillmen.